The American journal of the medical sciences
-
Early diagnosis, treatments of acute exacerbations, and chronic therapies have all improved the lifespan of cystic fibrosis patients; however, the natural history remains one of worsening bronchiectasis and obstructive airways impairment. The progression of disease leads to eventual respiratory failure, but some will have other acute respiratory complications that require intervention. In this report, we review the most common life-threatening respiratory complications of cystic fibrosis, including pneumothorax, massive hemoptysis, and respiratory failure.
-
At the present time, commercial aircraft cabins are required to be pressurized to the equivalent of 8,000 feet or less. Although in-flight medical emergencies are infrequent, some adults with pulmonary disease may experience significant physiological stress, exacerbation of their underlying illness, and severe hypoxemia during air travel. ⋯ The hypoxia altitude simulation test and the 6-minute walk test are useful when additional evaluation for supplemental in-flight oxygen is needed. Patients with an unstable condition, an acute exacerbation of their pulmonary disease, severe pulmonary hypertension (Class III and Class IV), or an active pneumothorax should not fly.
-
We investigated the outcome of a cohort of black Jamaican patients with systemic lupus erythematosus (SLE) with nephritis. In 66 patients, 0 (0%), 15 (23%), 4 (6%), 32 (48%), 6 (9%), and 3 (5%) had classes 1, II, III, IV, V, and VI, respectively. Six (9%) had interstitial nephritis. ⋯ The percent events free for death at 1 year was 93.4% in group 1 and 90.9% in group 2; at 2 years, 86.7% for group 1 and 90, 9% for group 2; and at 5 years was 86.7% for group 1 and 67.3% (29.5 to 88.0) for group 2. Sixteen patients (25.4%) developed ESRD or died. Prognosis was not different between the groups for ESRD or death (P = 0.22) or death alone (P = 0.63).
-
Elevated blood lead levels, a risk factor for cardiovascular disease, have been reported among patients with end-stage renal disease. We evaluated whether these higher levels are due to release of lead from the skeleton because of uremic bone disease. Fifty-one African-American patients with end-stage renal disease were recruited from 3 Tulane University dialysis programs between January and July 2005. ⋯ There were no differences in tibia and blood lead across levels of serum calcium, serum phosphorus, and the calcium phosphorus product (all P > 0.40). The high blood lead levels observed among dialysis patients do not appear to be the result of increased bone turnover. The causes of higher blood lead levels for these patients need to be identified and attenuated.
-
Repeated thoracenteses is indicated in patients with refractory, symptomatic transudative effusions. However, their effect on cytokines and fibrinolytic activity in pleural transudates remains unclear. ⋯ Repeated thoracenteses may induce local release of proinflammatory cytokines, VEGF and PAI-1, which may result in fibrin deposition and impair resolution of pleural transudates.